An Extension of the CONCERT Protocol (DIM18) (CONCERT PLUS)
This study has been terminated.
Information provided by (Responsible Party):
First received: June 25, 2010
Last updated: August 27, 2012
Last verified: August 2012
An open-label extension study of the CONCERT (DIM18) protocol evaluating the safety of dimebon (latrepirdine) in subjects with With Mild-to-Moderate Alzheimer's Disease on Donepezil.
|Study Design:||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients With Alzheimer's Disease|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Medivation, Inc.:
Primary Outcome Measures:
- Safety [ Time Frame: Through study discontinuation ] [ Designated as safety issue: No ]To evaluate the long-term safety and tolerability of dimebon (latrepirdine) in Alzheimer's disease (AD) patients who have completed 52 weeks of blinded treatment in the DIM18 (CONCERT) protocol.
|Study Start Date:||April 2010|
|Primary Completion Date:||May 2012 (Final data collection date for primary outcome measure)|
Contacts and Locations
No Contacts or Locations Provided